Screening of Reducing Agents for the PEGylation of Recombinant Human IL-10

被引:0
|
作者
Alexandre Ambrogelly
Collette Cutler
Brittany Paporello
机构
[1] Merck Research Laboratories,Bioprocess Development
来源
The Protein Journal | 2013年 / 32卷
关键词
Protein PEGylation; IL-10; Borane; Reductive alkylation; PEG; Pyridine; 2-Picoline; PEMB;
D O I
暂无
中图分类号
学科分类号
摘要
PEGylation is a technology commonly used to enhance the bioavailability of therapeutic proteins in patients. Reductive alkylation of a protein amino terminal alpha amine in the presence of a polyethylene glycol (PEG) chain derivatized with propionaldehyde and a reducing agent, typically sodium cyanoborohydride, is one of the technologies available to achieve quantitative and site specific PEGylation. While cyanoborohydride has proven to be a robust and efficient reagent for this type of reaction, it generates aqueous cyanide as a reaction by-product (and its corollary, the very volatile hydrogen cyanide). We report here the screening of reducing agents such as dimethylamine borane, trimethylamine borane, triethylamine borane, tert-butylamine borane, morpholine borane, pyridine borane, 2-picoline borane, and 5-ethyl-2-methyl-pyridine borane as alternatives to cyanoborohydride for the PEGylation of recombinant human IL-10. The results of our study show that pyridine borane and 2-picoline borane promote rhIL-10 PEGylation at levels comparable to those observed with cyanoborohydride.
引用
收藏
页码:337 / 342
页数:5
相关论文
共 50 条
  • [1] Screening of Reducing Agents for the PEGylation of Recombinant Human IL-10
    Ambrogelly, Alexandre
    Cutler, Collette
    Paporello, Brittany
    PROTEIN JOURNAL, 2013, 32 (05): : 337 - 342
  • [2] Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia - Effect of timing of recombinant human IL-10 administration
    Pajkrt, D
    Camoglio, L
    TielVanBuul, MCM
    deBruin, K
    Cutler, DL
    Affrime, MB
    Rikken, G
    vanderPoll, T
    tenCate, JW
    vanDeventer, SJH
    JOURNAL OF IMMUNOLOGY, 1997, 158 (08): : 3971 - 3977
  • [3] Preparation and validation of radio iodinated recombinant human IL-10 for the measurement of natural human antibodies against IL-10
    Rieper, Carina de Lemos
    Galle, Pia
    Svenson, Morten
    Pedersen, Bente Klarlund
    Hansen, Morten Bagge
    JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 350 (1-2) : 46 - 53
  • [4] Endogenous mouse IL-10 is upregulated by exogenously administered recombinant human IL-10 in mouse models of endotoxemia.
    Smith, SR
    Terminelli, C
    Denhardt, G
    Manfra, D
    Davies, L
    Narula, S
    FASEB JOURNAL, 1998, 12 (04): : A265 - A265
  • [5] IL-10 secretion in relation to the haplotypic structure of the human IL-10 locus
    Eskdale, J
    Gallagher, G
    Verweij, C
    Keijers, V
    Westendorp, R
    Huizinga, T
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1153 - 1153
  • [6] IL-10 or not IL-10: that is the question
    Dragana Jankovic
    Giorgio Trinchieri
    Nature Immunology, 2007, 8 : 1281 - 1283
  • [7] IL-10 or not IL-10: that is the question
    Jankovic, Dragana
    Trinchieri, Giorgio
    NATURE IMMUNOLOGY, 2007, 8 (12) : 1281 - 1283
  • [8] Differential effects of viral IL-10 and human IL-10 on human B cell lines.
    Beatty, PR
    Krama, SM
    Bromberg, JS
    Martinez, OM
    FASEB JOURNAL, 1998, 12 (04): : A265 - A265
  • [9] IL-10 in Humans: Lessons from the Gut, IL-10/IL-10 Receptor Deficiencies, and IL-10 Polymorphisms
    Engelhardt, Karin R.
    Grimbacher, Bodo
    INTERLEUKIN-10 IN HEALTH AND DISEASE, 2014, 380 : 1 - 18
  • [10] Disposition of recombinant human interleukin 10 (IL-10) in patients with various degrees of renal function.
    Lambrecht, LJ
    Swan, SK
    Cutler, DL
    Affrime, MB
    Radwanski, E
    Batra, V
    Macres, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII87 - PII87